All Drug Delivery articles
-
ArticleWhy more ribosomes can mean less protein in mRNA therapeutics
What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation speed could matter for the design of mRNA medicines.
-
NewsEngineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
A preclinical study combining chemically modified suppressor tRNAs with inhaled lipid nanoparticles has restored functional CFTR protein production across bronchial epithelial cells, mouse models and patient-derived organoids, offering a potential new therapeutic strategy for nonsense mutation-driven cystic fibrosis.
-
WebinarFrom antibody discovery to development: long-read sequencing in practice
As sequencing continues to grow in importance across biotherapeutic discovery and development, where can it make the biggest impact and how can fragmented workflows be overcome?
-
NewsReview challenges one-size-fits-all approach to OSCC drug delivery
A new review published in the European Journal of Pharmaceutics and Biopharmaceutics argues that no single local drug-delivery formulation will suit every oral squamous cell carcinoma tumour, urging researchers to anchor development in clinical and biological context from the outset.
-
NewsFirst multi-responsive foldamer-based gel offers new approach to controlled drug delivery
Researchers at the University of Birmingham have engineered a switchable gel built from synthetic foldamer molecules that responds to light, heat and acid — a platform with potential implications for controlled drug delivery and targeted therapeutic release.
-
NewsScientists identify a new vaccine design strategy for stronger HIV immunity
Two preclinical studies published in Science Translational Medicine suggest that the binding strength and structural repetitiveness of vaccine nanoparticles could be a critical design parameter in the long-running effort to generate broadly neutralising antibodies against HIV.
-
NewsNanomedicine for glioblastoma: overcoming the blood-brain barrier
A new review published in Chinese Neurosurgical Journal examines how nanoscale drug delivery systems could help overcome one of the most persistent obstacles in glioblastoma treatment – getting therapeutics across the blood–brain barrier and into tumour tissue.
-
NewsGlymphatic gene therapy platform targets brain’s glial cells precisely
A new gene therapy platform exploiting the brain’s glymphatic transport system and engineered AAV5 vectors could offer a targeted treatment route for multiple sclerosis, Huntington’s disease and rare white matter disorders.
-
ArticleWhy the blood–brain barrier blocks most drugs – and how ultrasound could help
The blood–brain barrier protects the brain from harmful substances, but it also prevents many medicines from reaching their target. Researchers are investigating whether focused ultrasound could safely improve drug delivery.
-
NewsWhat regenerative medicine can learn from multifunctional biomaterials
Researchers at the Indian Institute of Technology Gandhinagar have developed an injectable hydrogel incorporating a novel cerium–rutin metal–phenolic nanocomplex that simultaneously targets oxidative stress, inflammation and bacterial contamination in deep wounds—without the use of antibiotics.
-
NewsNon-endocytic delivery bypasses endosomal barriers for gene therapy
A new review examines how physical, bioengineered and biomimetic delivery platforms that bypass conventional endocytic uptake pathways could transform the clinical development of gene therapies, mRNA treatments and protein-based medicines.
-
ArticleHow spatial biology is tracking antibody drugs inside tumours
Many antibody therapies fail to reach all cancer cells within solid tumours. Researchers have developed a spatial biology technique that maps antibody distribution alongside the tumour microenvironment to investigate why.
-
ArticleSynthetic iMSCs: reprogramming ovarian cancer from the inside out
Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic iMSCs could reprogramme the tumour microenvironment and restore anti-tumour immunity.
-
NewsResearchers reveal how entinostat disrupts pancreatic cancer repair
Scientists at the Salk Institute have discovered how the investigational HDAC inhibitor entinostat disrupts DNA repair mechanisms in pancreatic cancer cells, potentially enabling more effective combination therapies with reduced toxicity through novel nanoparticle delivery systems.
-
NewsmRNA vaccine shows promise against childhood neuroblastoma cancer
Preclinical study demonstrates effectiveness of experimental mRNA vaccine against neuroblastoma, reducing tumour size by 70 percent and delaying development. RCSI researchers used peptide nanoparticles targeting GPC2 protein to direct immune response against cancer cells, offering potential new treatment approach for aggressive childhood malignancy.
-
NewsAI-designed proteins self-assemble into virus-like drug delivery structures
An international collaboration has developed AI-designed protein structures that self-assemble into virus-like nanocages using quasisymmetry principles, offering new possibilities for targeted drug delivery, vaccine development and genetic material transport without relying on modified viral proteins.
-
NewsCopper drug Cu(ATSM) reduces Alzheimer’s proteins by 42 percent in preclinical study
A copper-delivering compound has demonstrated the ability to restore blood-brain barrier clearance mechanisms, reducing amyloid-beta accumulation by 42 percent and improving spatial learning by 44 percent in Alzheimer’s disease models, according to research published in ACS Chemical Neuroscience.
-
NewsMineralised DNA hydrogel accelerates bone repair in preclinical studies
A mineralised DNA hydrogel has demonstrated accelerated bone repair and improved tissue mineralisation in preclinical studies, offering a potential new approach to treating difficult bone defects through combined immune regulation and sustained regeneration.
-
ArticleWhy targeted therapies are exposing the limits of animal models – and what comes next
Traditional preclinical models are struggling to keep pace with a new generation of targeted therapies. As regulators embrace new approach methodologies (NAMs), vascularised tissue platforms are offering a more human-relevant approach to predicting drug efficacy and safety.
-
NewsPlatinum-antibody conjugates enhance immunotherapy while reducing chemotherapy toxicity
A novel platinum(IV)-antibody conjugate platform delivers low-dose chemotherapy directly to tumours, upregulating MHC-I expression and enhancing anti-PD-1 responses while minimising systemic exposure. The approach addresses immune evasion mechanisms that limit checkpoint inhibitor efficacy.